A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

  • STATUS
    Recruiting
  • participants needed
    39
  • sponsor
    Beijing InnoCare Pharma Tech Co., Ltd.
Updated on 19 February 2024
lymphoma
b-cell lymphoma
diffuse large b-cell lymphoma
primary cns lymphoma

Summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Description

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with Recurrent/Refractory Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) will be evaluated in approximately 39 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects .

Details
Condition PCNSL, Secondary Central Nervous System Lymphoma
Age 18years - 75years
Treatment ICP-022
Clinical Study IdentifierNCT04438044
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Men and women 18, and 75 years of age
Histologically documented PCNSL, or histologically documented systemic diffuse large B-cell lymphoma (DLBCL) for SCNSL
Subjects with refractory or relapsed disease, one prior CNS directed therapy, and 4 systemic treatments
ECOG performance status of 0-2
Able to provide signed written informed consent

Exclusion Criteria

Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded
T-cell lymphoma
Patient requires more than 8 mg of dexamethasone daily or the equivalent
Non-hematological toxicity must recover to Grade 1 from prior anti-cancer therapy (except for alopecia)
Known active infection with HBV, HCV or HIV
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.